Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes
Japanese approval for MSD’s nine-valent HPV vaccine could be delayed beyond the originally expected June period after a flood of public comments were sent in for proposed revisions to associated rules, it has been learned. The nine-valent vaccine has been…
To read the full story
Related Article
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
February 5, 2021
- HPV Vaccines Clinically Significant in Japan, PMDA Says in Silgard 9 Review Report
July 28, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
- Japan Approves MSD’s 9-Valent HPV Vaccine 5 Years after Filing
July 21, 2020
- Japan Approval for MSD’s 9-Valent HPV Vaccine Delayed into July
June 30, 2020
- Panel OKs Ofev for PF-ILD; Label Expansion for Xtandi/Erleada, Prevenar and More
May 25, 2020
- MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
- Add MSD’s 9-Valent HPV Vaccine to National Immunization Program If Approved: Lawmakers
May 21, 2020
- MSD’s 9-Valent HPV Vaccine Up for Review in 1st Online PAFSC Meeting
April 16, 2020
- MSD’s 9-Valent HPV Vaccine Nearing Finish Line in Japan 5 Years after Filing, but Vaccination Policy Remains Iffy
April 13, 2020
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- MSD Applies for 9-Valent HPV Vaccine
July 29, 2015
REGULATORY
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
- Japan to Weigh Necessary Measures for FY2027 Revision: PM
October 15, 2026
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…